Latest Period
Q1 2026
Security Snapshot
Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share (MRKR) Institutional Ownership
CUSIP: 57055L206
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
36
Shares (Excl. Options)
3,903,241
Price
$1.30
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- MRKR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 3,903,241
- Total 13F value
- $5,073,847
- Portfolio coverage rank
- 0%
- Share change
- -274,260
- Value change
- -$405,239
- Number of holders
- 36
- Shares outstanding
- 16,869,505
- SEC-reported price per share
- $1.58
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MRKR - Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 57055L206.
- 36 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 36 to 36 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $6,027,366 to $5,073,847.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 36 institutions filings for Q1 2026.
Security key
57055L206
Latest holder period
Q1 2026
13F holders
36
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
MRKR full holder history
Marker Therapeutics, Inc. SEC filings
Marker Therapeutics, Inc. company facts
Marker Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 57055L206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
MRKR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 9.9% | -21% | $1,703,483 | +$45,291 | 1,670,081 | +2.7% | New Enterprise Associates 16, L.P. | 13 Nov 2025 |
| Alyeska Investment Group, L.P. | 9.9% | -0.9% | $1,143,378 | +$188,600 | 1,280,952 | +20% | Alyeska Investment Group, L.P. | 30 Sep 2025 |
| Blue Owl Capital Holdings LP | 10% | +96% | $1,431,356 | +$727,459 | 1,127,052 | +103% | Blue Owl Capital Holdings LP | 31 Mar 2025 |
As of 31 Mar 2026, 36 institutional investors reported holding 3,903,241 shares of Marker Therapeutics, Inc. - Common Stock, par value $0.001 per share (MRKR). This represents 23% of the company’s total 16,869,505 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
23%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 9.6% | 1,625,678 | 0% | 0.12% | $2,113,381 |
| Blue Owl Capital Holdings LP | 3.3% | 554,250 | 0% | 0.19% | $720,525 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 389,319 | 0% | 0% | $506,115 |
| Aisling Capital Management LP | 1.9% | 325,370 | 0% | 0.09% | $422,981 |
| RENAISSANCE TECHNOLOGIES LLC | 1% | 175,294 | +42% | 0% | $227,882 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95% | 160,910 | +23% | 0% | $209,206 |
| OSAIC HOLDINGS, INC. | 0.55% | 93,121 | -1.4% | 0% | $121,057 |
| VANGUARD FIDUCIARY TRUST CO | 0.52% | 87,269 | 0% | 0% | $113,450 |
| LPL Financial LLC | 0.49% | 83,047 | -0.24% | 0% | $107,961 |
| XTX Topco Ltd | 0.38% | 63,567 | +9.5% | 0% | $82,637 |
| TWO SIGMA INVESTMENTS, LP | 0.36% | 61,001 | -38% | 0% | $79,301 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.29% | 48,780 | 0% | $63,414 | |
| JANE STREET GROUP, LLC | 0.22% | 36,303 | -10% | 0% | $47,194 |
| UBS Group AG | 0.19% | 32,369 | -81% | 0% | $42,080 |
| Invst, LLC | 0.17% | 29,000 | +7.4% | 0% | $37,700 |
| NORTHERN TRUST CORP | 0.15% | 26,009 | 0% | 0% | $33,812 |
| STATE STREET CORP | 0.12% | 20,948 | 0% | 0% | $27,232 |
| Creative Planning | 0.1% | 17,312 | 0% | 0% | $22,506 |
| Ashton Thomas Private Wealth, LLC | 0.1% | 16,400 | +64% | 0% | $21,320 |
| MATRIX ASSET ADVISORS INC/NY | 0.09% | 15,000 | 0% | 0% | $19,500 |
| HRT FINANCIAL LP | 0.07% | 11,852 | -15% | 0% | $15,000 |
| TWO SIGMA SECURITIES, LLC | 0.07% | 11,460 | 0% | $14,898 | |
| FIFTH THIRD BANCORP | 0.06% | 10,000 | 0% | 0% | $13,000 |
| Tower Research Capital LLC (TRC) | 0.02% | 3,137 | +339% | 0% | $4,078 |
| Vanguard Global Advisers, LLC | 0.01% | 2,512 | 0% | 0% | $3,266 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,903,241 | $5,073,847 | -$405,239 | $1.30 | 36 |
| 2025 Q4 | 4,044,475 | $6,027,366 | +$898,868 | $1.49 | 36 |
| 2025 Q3 | 3,455,371 | $3,085,979 | -$181,920 | $0.89 | 32 |
| 2025 Q2 | 3,410,487 | $5,218,067 | -$775,167 | $1.53 | 31 |
| 2025 Q1 | 4,023,536 | $4,948,972 | +$278,481 | $1.23 | 31 |
| 2024 Q4 | 3,484,395 | $10,763,745 | +$4,748,926 | $3.11 | 31 |
| 2024 Q3 | 1,936,917 | $5,462,150 | -$201,922 | $2.82 | 27 |
| 2024 Q2 | 1,938,345 | $10,524,473 | +$162,842 | $5.43 | 26 |
| 2024 Q1 | 1,911,504 | $8,219,717 | +$19,050 | $4.30 | 26 |
| 2023 Q4 | 1,906,940 | $10,488,483 | +$197,065 | $5.50 | 24 |
| 2023 Q3 | 1,871,217 | $8,502,131 | +$261,000 | $4.54 | 26 |
| 2023 Q2 | 1,824,779 | $5,655,903 | +$1,085,797 | $3.10 | 27 |
| 2023 Q1 | 1,624,962 | $1,154,593 | +$1,154,593 | $0.71 | 26 |